Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 7 7 7 versus PIMTREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 7 7 7 versus PIMTREA.
CYCLAFEM 7/7/7 vs PIMTREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Ethinyl estradiol suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis; norethindrone induces endometrial changes that inhibit implantation and thickens cervical mucus.
PIMTREA is a small molecule inhibitor of the interaction between the PD-1 receptor and its ligands PD-L1 and PD-L2, acting as an immune checkpoint inhibitor to restore anti-tumor T-cell activity.
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 0.75 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days. Dispensed in a 21-tablet pack with 7 placebo tablets. For contraception, take one tablet daily at same time each day for 28 days; begin next pack after 28-day cycle.
Intravenous 1000 mg/m2 over 10 minutes on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal half-life: 5-13 hours (mean 8 hrs); clinical context: supports every-28-day dosing interval for intramuscular depot.
Terminal elimination half-life of 2.5 to 4 hours; prolonged in renal impairment (up to 6–12 hours in severe impairment).
Renal: ~50-60% as conjugated metabolites; Fecal: ~30-40% via bile; <1% unchanged.
Primarily renal (approximately 70% as unchanged drug), with biliary/fecal excretion accounting for the remainder. Less than 5% metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive